Physics / mechanism
Life Sciences Tools & Services (LS T&S) covers the instruments, reagents, consumables, software, and contract services that enable biological research, drug discovery, and clinical diagnostics — distinct from therapeutics themselves. Key segments: analytical instruments (mass spec, sequencing, flow cytometry), lab automation, CRO/CDMO services, and bioinformatics. Market ~$120B globally, growing 7% CAGR. Dominant players: Thermo Fisher ($43B revenue), Danaher, Illumina, Waters, Bruker. The defining dynamic is the razor/blade model — instruments placed at low margin, consumables and service contracts generating 60–70% gross margins. Platform stickiness is high; switching costs in installed-base workflows are structural.
Competitive landscape
Adjacent pressure comes from three directions. First, semiconductor-adjacent biosensors (nanopore sequencing, CMOS-integrated arrays, photonic lab-on-chip) threatening incumbent optical instrument stacks. Second, AI-driven virtual screening compressing wet-lab throughput requirements, partially commoditising HTS services. Third, synthetic biology tools (cell-free systems, microfluidics) redistributing spend away from traditional analytical instruments toward enabling hardware.
| Approach | Margin profile | Disruption vector |
|---|---|---|
| Traditional instruments | High (consumables) | Photonic/CMOS integration |
| CRO/CDMO services | Mid (labour-intensive) | Automation + AI |
| Digital/AI biology platforms | SaaS-like, early | Reduces wet-lab volume |
Companies using
Connected ideas
Sources
Frontier (open questions)
- To be added.